
Ardian-backed Laboratoires Anios expands with Inibsa Hospital
French disinfection specialist Laboratoires Anios, backed by Ardian since 2013, has bolted on Spain's Inibsa Hospital, the disinfection branch of Inibsa Laboratorios.
The acquisition marks the group's fourth acquisition under Ardian's ownership. The GP had invested in the French pharmaceutical company in a mid-market MBO in 2013, acquiring it from French multinational Air Liquide through its €2.41bn LBO Fund V. As a result of the transaction, the GP's management team and employees owned nearly half of the business.
Previous bolt-ons included Endoclear – a Brazilian company specialised in automatic endoscope disinfection processes – and Turkish group Deren last year, as well as the French business Soluscope in 2014.
This new bolt-on is in line with Ardian's intention to develop the group on an international scale. Anios's aim is to generate 50% of its turnover – currently sitting at €220m – outside France by 2020.
Company
Founded in 1948 in Barcelona, Inibsa Hospital is a Spanish pharmaceutical company specialising in disinfection. It manufactures and commercialises products for the odontology, hospital and pharmaceutical sectors.
The company registered a €7m turnover in 2015.
People
Ardian – Philippe Poletti (senior managing director).
Advisers
Equity – Grant Thornton (financial due diligence); Garrigues (legal).
Vendor – Deloitte (financial due diligence).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater